1. Kenneth Kaushansky and Thomas J. Kipps. Hematopoietic agents, Goodman & Gilman’s: The Pharmacological basics of therapeutics. 12th Edition. New York Mc Graw Hill Medical 2011. Page - 1076.
2. Gerald G. Briggs and Roger K. Freeman. E. A reference guide to fetal and neonatal risk: Drugs in Pregnancy and Lactation. Tenth Edition. 2015. Page – 1325-1327.
3. University of Utah. Efficacy and Safety of Eltrombopag In Patients with Severe and Very Severe Aplastic Anemia. NIH U.S. National Library of Medicine ClinicalTrials.gov. [Revised on October 2017] [Accessed 29th October 2020] https://clinicaltrials.gov/ct2/show/NCT01703169
4. Jyothis Purushothaman, Kochuthresia J. Puthumana, Aswath Kumar, Susheela J. Innah and Sareena Gilvaz. A case of refractory immune thrombocytopenia in pregnancy managed with elthrombopag. NCBI; PMC National Library of Medicine, National Institute of Health. July-December 2016 [Accessed 29th October 2020] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993088/#:~:text=Eltrombopag%20has%20been%20assigned%20to,only%20when%20benefit%20outweighs%20risk.
5. Novartis Farmacéutica SA. Electronic Medicines Compendium (EMC); [Revised on January 2020] [Accessed 29th October 2020] https://www.medicines.org.uk/emc/files/pil.7820.pdf
6. GlaxoSmithKline. U.S. Food & Drug Administration; [Revised on October 2008] [Accessed 29th October 2020] https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022291lbl.pdf